Sarah Jane Tribble
Sarah Jane Tribble joined Kaiser Health News from Ideastream — the NPR/PBS member station in Cleveland, Ohio — where she covered health, health policy and the business of health care. She won an Emmy as host of the station’s health care programming and was a regular contributor on NPR’s Morning Edition and All Things Considered.
-
The potential for conflict of interest when health policy experts also serve on the boards of pharma companies
The issue of conflicts of interest has become more pressing in recent years as drug prices soar and healthcare companies reach out to the academic and policy community for advice — often with generous payments attached, ethics experts say.
-
Trump’s drug cost cutting plans include transparency, but critics doubt much will change
In his plans to cut sky-high drug prices unveiled Friday, Trump said that increasing industry competition will help Americans save at the pharmacy counter.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Trump’s view on drug costs: Talk vs. the truth
President Donald Trump has railed against the high price of prescription drugs, yet many Americans aren’t seeing a change in what they pay out-of-pocket. Here’s a look at the rhetoric thus far versus the results.
-
How a drugmaker converted the “abortion pill” into a lucrative orphan drug
The story of Korlym highlights how America’s drug development system can turn an old drug into a new one that treats relatively
few — but often very desperate — patients. -
Trump’s budget flirts with combating high drug prices
The White House’s proposal, which comes after Congress passed a two-year spending deal last week, sets the tone for the administration’s focus on prescription drugs.
-
Experts offered Senate HELP committee 9 proposals to cut drug prices. Here are the odds of passage
At a hearing held by the Senate Health, Education, Labor and Pensions Committee, experts made nine proposals to lower drug prices. Here’s an analysis on the likelihood of action being taken on each of them.
-
Drug discount program 340B is at center of debate between CMS, lawmakers and hospitals
The 340B program requires pharmaceutical companies to give steep discounts to hospitals and clinics that serve high volumes of low-income patients. But a move by CMS to cut Medicare payments for hospitals enrolled in the program has sparked a debate over the program’s future.
-
CMS is looking for ideas on reducing drug prices for Medicare Part D
Medicare officials requested comments late Thursday on how to use discounts and rebates to help decrease what enrollees pay for prescriptions.
-
States investigate pharma companies, CVS Health as diabetes drug prices reach record highs
The United States is one of the few developed countries without regulations on prescription drug pricing.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Concerned with abuse of orphan drug program, FDA is rethinking how it approves these medications
The Food and Drug Administration is changing the way it approves medicines known as “orphan drugs” after revelations that drugmakers may be abusing a law intended to help patients with rare diseases.
-
Are pharma industry companies converting patients with orphan diseases into lobbyists?
Behind-the-scenes partnerships between the pharmaceutical industry and advocacy groups may work against lowering the cost of high-priced drugs.
-
Government Accountability Office will investigate potential abuses with Orphan Drug Act
Reports of five- and six-figure annual price tags for orphan drugs have concerned U.S. senators.
-
High drug price concerns spur request for GAO investigation of Orphan Drug Act
Sens. Orrin Hatch (R-Utah), Chuck Grassley (R-Iowa) and Tom Cotton (R-Arkansas.) raised the possibility that regulatory or legislative changes might be needed “to preserve the intent of this vital law” that gives drugmakers lucrative incentives to develop drugs for rare diseases.
-
5 reasons for the latest drug cost firestorm, this time over Emflaza’s price tag
Emflaza, the brand name for deflazacort, has never been approved for sale in the United States, but the steroid has been sold for decades in other countries — at much lower prices
-
Grassley opens probe into Orphan Drug Act abuses
In a statement, Grassley said the inquiry is “based on reporting from Kaiser Health News” and strong consumer concern about high drug prices.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
